drugset
drugset / Trial / NCT00089167

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

NCT00089167 ↗

Phase 2 Completed Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab
Open-labelTreatment

Summary

RATIONALE: Drugs such as melphalan, thalidomide, and dexamethasone may be effective in treating patients with primary systemic amyloidosis. PURPOSE: This phase II trial is studying how well giving melphalan together with thalidomide and dexamethasone works in treating patients with primary systemic amyloidosis.

Timeline

Start
2002-05
Primary completion
2007-12
Completion
—

Publications

  • Results Cohen AD, Zhou P, Reich L, et al.: Risk-adapted intravenous melphalan followed by adjuvant dexamethasone (D) and thalidomide (T) for newly diagnosed patients with Systemic AL Amyloidosis (AL): interim results of a phase II study. [Abstract] Blood 104 (11): A-542, 2004.

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule — —
Subject Melphalan Small molecule — Intravenous
Subject Thalidomide Other / unclassified — —
Background filgrastim Protein / enzyme biologic — —

Indications

plasma cell myeloma